GENETIC SUSCEPTIBILITY TO LIPID-LOWERING DRUG-INDUCED MYOPATHIES

对降脂药物引起的肌病的遗传易感性

• 批准号: 7952194
• 负责人: MICHAEL H. WEISMAN
• 金额: $ 0.09万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952194
• 关键词: Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Funding; Gene Mutation; Genetic Predisposition to Disease; Grant; High Prevalence; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Individual; Institution; Lipids; Metabolic; Myopathy; Patients; Pharmaceutical Preparations; Recruitment Activity; Research; Research Personnel; Resources; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine if individuals who are treated with HMG-CoA reductase inhibitors and develop myopathy have a higher prevalence of genetic mutations causing metabolic muscle diseases. Two-hundred patients will be recruited into the study.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定接受HMG-CoA还原酶抑制剂治疗并发展为肌病的个体是否有更高的导致代谢性肌肉疾病的基因突变患病率。200名患者将被招募到这项研究中。